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Abstract
Brain metastasis from non-small cell lung cancer remains a challenge to
physicians. It occurs in 30% of patients with advanced stage adenocarci-
noma of lung and is often regarded as the ominous sign of disease progres-
sion and death. Alectinib is likely to be a promising agent, even after the
failure of crizotinib and ceritinib, for patients with anaplastic lymphoma
kinase (ALK) -driven non-small cell lung cancer with brain metastasis,
resulting in a durable response for both intracranial and extra-cranial
diseases.
Introduction
We report the case of a young man who had ALK-driven
adenocarcinoma of the lung with progressive brain metas-
tases despite targeted therapy and chemotherapy. Salvage
treatment with alectinib resulted in a durable response in
both systemic and intracranial diseases. The rationale of
therapeutic selection among various ALK tyrosine kinase
inhibitors (TKI) is illustrated with this case in the era of
personalized lung cancer treatment.
Case Report
A 36-year-old Chinese man was ﬁrst diagnosed to have
stage IIIB adenocarcinoma of the lung in 2008. He was
treated with paclitaxel, carboplatin, and bevacizumab for
six cycles, but the disease progressed with new intrapul-
monary metastases and two right parietal cystic brain
metastases. He received whole brain irradiation (WBRT)
followed by pemetrexed for ﬁve cycles. The disease pro-
gressed again. At that time, the ALK gene rearrangement
test was not readily available. He had an epidermal growth
factor receptor wild-type tumour; nonetheless, erlotinib
was started as third-line chemotherapy despite having only
modest beneﬁt. Disease progressed after 4 months. At that
time, crizotinib was undergoing clinical trials in the setting
of second-line treatment and beyond. His archived tumour
sample tested positive for ALK by ﬂuorescent in situ
hybridization assay. Crizotinib (250 mg twice daily) was
started under trial protocol. There was good partial
response for 16 months until a new right high parietal
metastasis developed. In view of the tiny, asymptomatic
brain metastasis and still responding extra-cranial disease,
crizotinib was continued for another 6 months until frank
extra-cranial progression was recorded. He was recruited
to another clinical trial with ceritinib (750 mg daily). He
had gastrointestinal side effects and drug-induced hepati-
tis, which required temporary suspension of ceritinib for
3 weeks at the ﬁfth month. The disease remained stable
until 7 months later, when there was progression in the
primary tumour and a new brain metastasis in the lower
part of medulla oblongata. Ceritinib was continued despite
progression, while CyberKnife was administered to the
brainstem lesion. The disease remained stable for another
22 months. He could tolerate ceritinib with mild gastroin-
testinal problems. Subsequently, there was symptomatic
progressive disease in the brain. Creitinib was switched to
alectinib 600 mg twice daily after 31 months. There was
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partial response in the medullary metastasis, with stable
disease at extra-cranial sites (Fig. 1). These responses have
been maintained for at least 8 months of alectinib treat-
ment at the time of writing. During the treatment course,
alectinib was temporarily withheld due to myositis, with
creatine kinase rising to 2673 U/L (normal: 65–355 U/L).
Upon resumption of alectinib, there was no recurrence of
myositis. Overall, he has satisfactory tolerance to alectinib,
while there is sustained disease response in both intracra-
nial and extra-cranial sites at around 8 years after
diagnosis.
Discussion
Brain metastases remain a major challenge in thoracic
oncology. Stereotactic radiosurgery is reserved for a
limited number of small brain metastases. WBRT is still
the treatment of choice for multiple brain metastases
despite causing signiﬁcant morbidities. The beneﬁt from
systemic therapy largely depends on its ability to cross
the blood–brain barrier. Chemotherapy is considered
less effective than radiotherapy for treating brain
metastasis.
Central nervous system (CNS) penetration is also a
problem for earlier TKI. Crizotinib only has modest activ-
ity against brain metastases. The reported cerebrospinal
ﬂuid-to-plasma ratio of crizotinib was only 0.0026. In a
study involving 343 patients with ALK-positive lung can-
cer, in which 79 patients received treatment for brain
metastases, crizotinib had an intracranial disease control
rate of 85% at 12 weeks, which decreased to 56% at
24 weeks [1]. The durability of intracranial disease control
is a concern as CNS relapses may result in rapid neurologi-
cal deterioration. The second generation ALK inhibitor,
ceritinib, also has activity in brain metastasis, with an
overall response rate of 54% [2]. Unfortunately, its use is
limited by its toxicities. Diarrhoea, nausea, and vomiting
occurred in 86, 80, and 60% of patients, respectively.
Drug-induced hepatitis is common, occurring in up to
80% patients with 27% having grade 3–4 hepatitis. The
adverse effects remain a hurdle to successful and tolerable
treatment.
Alectinib has been shown to have important clinical
activity in brain metastases, including CNS relapse with
other ALK inhibitors. In a phase II trial with 84 patients,
the CNS disease control rate of alectinib was 83% with a
median duration of CNS response at 10 months [3]. Its
activity against brain metastases was similar regardless of
previous radiation therapy or not. Alectinib also demon-
strated improved progression-free survival relative to cri-
zotinib among patients with brain metastases in the
J-ALEX study [4]. In a case series, alectinib demonstrated
Figure 1. T2-weighted magnetic resonance imaging of the brainstem showing partial response in the medulla oblongata metastasis with alectinib
treatment. (a) Medulla oblongata metastasis while on ceritinib for 30 months and after CyberKnife treatment, measuring 10 × 13 × 18 mm.
(b) Medulla oblongata metastasis after 6 months of alectinib treatment, which showed interval reduction in size and enhancement, measur-
ing 3 × 5 mm.
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signiﬁcant anti-tumour activity in ALK-positive patients
with leptomeningeal and brain metastases who had prior
treatment with crizotinib and ceritinib [5]
Our case also reﬂects some of these ﬁndings from previ-
ous reports. Crizotinib has some activity against brain
metastases but has limited durability. Ceritinib has signiﬁ-
cant CNS activity, but its toxicities often warrant dose
reduction or transient withholding, resulting in CNS
relapse. In our case, the CNS disease was under control for
16 and 7 months while on crizotinib and ceritinib, respec-
tively. Crizotinib achieved partial response in the brain
metastases, while ceritinib led to disease stabilization. On
the other hand, salvage treatment with alectinib resulted in
signiﬁcant partial response both intracranially and extra-
cranially for at least 8 months at the time of writing. This
could result from both better tolerability and potentially
more potent ALK inhibition of alectinib compared with
crizotinib and ceritinib. Our anecdotal experience suggests
that alectinib is a reasonable choice of treatment for
patients with ALK-driven non-small cell lung carcinoma
with brain metastasis even after the failure of existing ALK
inhibitors.
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